Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29835995 | 0.87 | KDM4E (0.47) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL22918243 | 0.87 | KDM4E (0.47) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15270946 | 0.86 | KDM4E (0.50) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31053274 | 0.86 | KDM4E (0.50) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15270663 | 0.86 | KMT2A (0.50) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5672753 | 0.86 | ALDH1A1 (0.43) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2561757 | 0.85 | SLC6A4 (0.47) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL154368 | 0.85 | HSD17B10 (0.68) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6307470 | 0.85 | CYP3A4 (0.61) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2557947 | 0.84 | SLC6A4 (0.49) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665339-A1 | INHIBITING ALPHA V BETA 8 INTEGRIN | Morphic Therapeutic, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2024173570-A1 | INHIBITING αvβ8 INTEGRIN | MORPHIC THERAPEUTIC, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| US-20240109899-A1 | BENZOFURAN COMPOUNDS AS STING AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-04 | — | — | US | disclosed |
| US-20240041837-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. | 2024-02-08 | — | — | US | disclosed |
| US-11666557-B2 | Triazolone compounds and uses thereof | TEMPEST THERAPEUTICS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11666557-B2 | Triazolone compounds and uses thereof | TEMPEST THERAPEUTICS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11666557-B2 | Triazolone compounds and uses thereof | TEMPEST THERAPEUTICS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| WO-2022169921-A1 | BENZOFURAN COMPOUNDS AS STING AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-08-11 | — | — | WO | disclosed |
| US-11267779-B2 | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis | PROMETIC PHARMA SMT LIMITED (GB) | 2022-03-08 | — | — | US | disclosed |
| US-20210002202-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses Thereof | PROMETIC BIOSCIENCES, INC. (CA) | 2021-01-07 | — | — | US | disclosed |
| US-20090137610-A1 | SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2009-05-28 | — | — | US | disclosed |
| EP-1979355-A1 | SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2008-10-15 | — | — | EP | disclosed |
| EP-1894911-A1 | VITAMIN D-LIKE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-03-05 | — | — | EP | disclosed |
| WO-2007087448-A1 | SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007087448-A1 | SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2007-08-02 | — | — | WO | disclosed |
| US-20040214888-A1 | Carboxylic acid derivative and medicine comprising salt or ester of the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-10-28 | — | — | US | disclosed |
| EP-1394147-A1 | CARBOXYLIC ACID DERIVATIVE AND MEDICINE COMPRISING SALT OR ESTER OF THE SAME | Eisai Co., Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
| EP-1163214-A1 | GAMMA-KETOACID DIPEPTIDES AS INHIBITORS OF CASPASE-3 | Merck Frosst Canada & Co. (CA) | 2001-12-19 | — | — | EP | disclosed |
| US-6225288-B1 | IMPLICATED IN MODULATING APOPTOSIS; TREATMENT OF:CARDIAC AND CEREBRAL ISCHEMIA/REPERFUSION INJURY, SPINAL CORD INJURY AND ORGAN DAMAGE DURING TRANSPLANTATION, CHRONIC NEURODEGENERATIVE DISEASES, IMMUNODEFICIENCY, DIABETES, ALOPECIA, AGING | MERK FROSST CANADA & CO. (CA) | 2001-05-01 | — | — | US | disclosed |
| WO-2000055127-A1 | GAMMA-KETOACID DIPEPTIDES AS INHIBITORS OF CASPASE-3 | MERCK FROSST CANADA & CO. (CA) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11666557-B2 | Triazolone compounds and uses thereof | PPARA, PPARG, PPARD | KDM4E 2133/4885ALDH1A1 589/4885MEN1 3885/4885 |
| US-20240041837-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | PPARA, PPARG, PPARD | KDM4E 2133/4885ALDH1A1 589/4885MEN1 3885/4885 |
| US-20210002202-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses Thereof | TYR, PAH, REN | KDM4E 1702/4885ALDH1A1 190/4885MEN1 4643/4885 |
| US-20090137610-A1 | SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS | PPARD, PPARG, PPARA | KDM4E 3045/4885ALDH1A1 736/4885MEN1 4719/4885 |
| US-20240109899-A1 | BENZOFURAN COMPOUNDS AS STING AGONISTS | STING1, MAVS, IRF3 | KDM4E 2249/4885ALDH1A1 3028/4885MEN1 2677/4885 |
| US-20040214888-A1 | Carboxylic acid derivative and medicine comprising salt or ester of the same | GPR119, NR3C1, INSR | KDM4E 3724/4885ALDH1A1 1626/4885MEN1 3653/4885 |
| US-11267779-B2 | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis | PAH, HRH3, CFH | KDM4E 1111/4885ALDH1A1 402/4885MEN1 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.